The Rise of Biosimilars: Regulatory Pathways and Market Outlook
Biosimilars are changing the way healthcare systems manage the high cost of advanced medicines.
September 19, 2025
by Nurah Ekhlaque
The Role of Biosimilars
Biological drugs are therapeutics that are made by living organisms or are created from cells and tissues, and include therapeutic proteins and monoclonal antibodies.
February 12, 2025
by Suzanne Elvidge
Global Drug Innovation Trend and Its Market Landscape
The creation of novel medications, treatments, and medical equipment that improve patient care and treatment results or outcomes is referred to as pharmaceutical innovation.
September 25, 2024
by Shruti Talashi
Polpharma Biologics Announces Approval of Europe’s First and Only Biosimilar for Multiple Sclerosis - Tyruko® (Natalizumab)
Polpharma Biologics, today announced that the European Commission (EC) has approved Tyruko® (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis (MS) in Europe.
November 6, 2023
by B3C newswire
Polpharma Biologics Announces First-of-a-Kind Multiple Sclerosis Biosimilar Natalizumab Receives Positive CHMP Opinion
Polpharma biologics announces first-of-a-kind multiple sclerosis biosimilar natalizumab receives positive CHMP opinion.
July 24, 2023
by PharmaSources
What’s the known so far with Medicines & Good Manufacturing Practices?
Be it a pharmaceutical or bio-pharmaceutical, both are regulated by the FDA, US. And it is mandatory for both kinds of manufacturing companies to follow the current Good manufacturing practices (cGMP) inprocess of getting certified from USFDA.
May 16, 2023
by Shruti Talashi
Participants Dosed on Adessia in Germany in a Phase 1 Trial, a First for an Adalimumab Biosimilar Candidate Developed in Africa
Group in strategic collaboration with Divine Genes to offer genetic tests related to reproductive health in Malaysia and
overseas.
March 7, 2023
by PharmaSources
The Coming Successor and the Ending Humira
On January 31, Amgen announced that its Humira (Adalimumab) biosimilar, Amjevita (adalimumab-atto), had entered into the American market officially.And Amjevita is also the first adalimumab biosimilar approved by FDA.
March 1, 2023
by Yi/PharmaSources
Biosimilar Tocilizumab Injection approved for marketing
Biosimilar Tocilizumab Injection approved for marketing.
January 16, 2023
by www.nmpa.com
IGBA launches whitepaper on global generic and biosimilar medicines industry
It covers opportunities, challenges and disruptions for the industry, vision for 2030 as well as actions needed to achieve this vision.
July 8, 2021
by expresspharma
No plans to enter vaccine production as it needs different manufacturing infra: Dilip Sanghvi
Sun Pharma has no immediate plans to enter into vaccine production as getting into the vertical would require an altogether different manufacturing set-up, as per a top company official.
June 16, 2021
by expresspharma
Chemotherapy uptake to gradually decrease with arrival of novel therapies and biosimilars- GlobalData
Trends in chemotherapy sales are expected to vary widely with CAGRs ranging from -14.92 per cent to 8.40 per cent across 15 major.
March 26, 2021
by expresspharma